BRIEF published on 04/29/2026 at 13:44, 6 months 1 day ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 6 months 1 day ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
BRIEF published on 04/29/2026 at 13:44, 6 months 1 day ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 6 months 1 day ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
PRESS RELEASE published on 04/29/2026 at 13:39, 6 months 1 day ago Informations privilégiées / Autres communiqués Medincell annonce une forte croissance des ventes de UZEDY aux Etats-Unis, une formulation injectable approuvée par la FDA pour la schizophrénie et le trouble bipolaire. De nouvelles avancées pour l'olanzapine LAI sont également en cours FDA Schizophrénie Medincell Teva UZEDY
PRESS RELEASE published on 04/29/2026 at 13:39, 6 months 1 day ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
BRIEF published on 04/20/2026 at 11:18, 6 months 10 days ago Franchissement de seuil par BNP Paribas Développement chez MEDINCELL Euronext Paris Droits De Vote Franchissement De Seuil BNP Paribas Medincell
BRIEF published on 04/20/2026 at 11:18, 6 months 10 days ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
PRESS RELEASE published on 04/20/2026 at 11:13, 6 months 10 days ago Franchissement de seuil Déclaration de franchissement de seuil par BNP Paribas Développement concernant MEDINCELL sur Euronext Paris Euronext Paris Droits De Vote Franchissement De Seuil Medincell BNP Paribas Développement
BRIEF published on 04/02/2026 at 19:05, 6 months 28 days ago Medincell : Mise à jour sur le capital et les droits de vote Droits De Vote Euronext Capital Social Actions AMF
Published on 10/30/2026 at 23:35, 1 hour 38 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 hour 43 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 4 hours 26 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 6 hours 13 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 9 hours 43 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 2 hours 24 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 6 hours 35 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 2 hours 13 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 2 hours 13 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
